April 17th 2024
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
SOLD: 9-Week's of Trastuzumab Falls Short in HER2-Positive Breast Cancer
December 8th 2017Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 1 year of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer.